In NSCLC A549 cell lines, erlotinib induced ROS-mediated apoptosis via activation of the c-Jun N-terminal kinase (JNK) pathway, leading ultimately to EGFR inhibition and a therapeutic response. Here, EGFR is linked to non-small cell lung carcinoma.